Pages that link to "Q26766341"
Jump to navigation
Jump to search
The following pages link to Targeting of Mutant p53 and the Cellular Redox Balance by APR-246 as a Strategy for Efficient Cancer Therapy (Q26766341):
Displaying 27 items.
- Elevated PRC1 in gastric carcinoma exerts oncogenic function and is targeted by piperlongumine in a p53-dependent manner (Q33844651) (← links)
- Understanding cell cycle and cell death regulation provides novel weapons against human diseases. (Q39218376) (← links)
- Mutant p53 in Cancer: Accumulation, Gain-of-Function, and Therapy (Q39229004) (← links)
- Overaccumulation of p53-mediated autophagy protects against betulinic acid-induced apoptotic cell death in colorectal cancer cells (Q41911815) (← links)
- Mutant p53-Nrf2 axis regulates the proteasome machinery in cancer (Q42325001) (← links)
- Targeting mutant p53 for cancer therapy (Q42433820) (← links)
- PRIMA-1 and PRIMA-1Met (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies (Q47274927) (← links)
- Synergistic Rescue of Nonsense Mutant Tumor Suppressor p53 by Combination Treatment with Aminoglycosides and Mdm2 Inhibitors. (Q47721091) (← links)
- PARP-1 inhibitors sensitize HNSCC cells to APR-246 by inactivation of thioredoxin reductase 1 (TrxR1) and promotion of ROS accumulation (Q48507317) (← links)
- Defining key concepts of intestinal and epithelial cancer biology through the use of mouse models (Q49579860) (← links)
- Piperlongumine and p53-reactivator APR-246 selectively induce cell death in HNSCC by targeting GSTP1. (Q49952370) (← links)
- A combination of p53-activating APR-246 and phosphatidylserine-targeting antibody potently inhibits tumor development in hormone-dependent mutant p53-expressing breast cancer xenografts. (Q52722381) (← links)
- Targeting the DNA Damage Response in OSCC with TP53 Mutations. (Q52729908) (← links)
- New aspects of antiproliferative activity of 4-hydroxybenzyl isothiocyanate, a natural H2S-donor. (Q55039774) (← links)
- Mutant p53 tunes the NRF2-dependent antioxidant response to support survival of cancer cells. (Q55281959) (← links)
- Genomic profiles of primary and metastatic esophageal adenocarcinoma identified via digital sorting of pure cell populations: results from a case report (Q58748552) (← links)
- Epigenetic therapy for ovarian cancer: promise and progress (Q61448020) (← links)
- Accuracy of analysis of cfDNA for detection of single nucleotide variants and copy number variants in breast cancer (Q64052201) (← links)
- New and Emerging Targeted Therapies for Pediatric Acute Myeloid Leukemia (AML) (Q89683082) (← links)
- Evaluation of the CRISPR/Cas9 directed mutant TP53 gene repairing effect in human prostate cancer cell line PC-3 (Q90392618) (← links)
- Short-term organoid culture for drug sensitivity testing of high-grade serous carcinoma (Q91608882) (← links)
- p53 mutant-type in human prostate cancer cells determines the sensitivity to phenethyl isothiocyanate induced growth inhibition (Q91895544) (← links)
- Therapeutic targeting of mutant p53 in pediatric acute lymphoblastic leukemia (Q91898958) (← links)
- Novel therapy in Acute myeloid leukemia (AML): moving toward targeted approaches (Q92005700) (← links)
- p53 as a hub in cellular redox regulation and therapeutic target in cancer (Q92500329) (← links)
- p53 balances between tissue hierarchy and anarchy (Q92701441) (← links)
- The Undervalued Avenue to Reinstate Tumor Suppressor Functionality of the p53 Protein Family for Improved Cancer Therapy-Drug Repurposing (Q99708992) (← links)